About Sitari PharmaceuticalsSitari Pharmaceuticals, Inc. develops treatments for multiple disease indications such as celiac disease. The company offers targeted inhibitors of Transglutaminase 2 (TG2) with the potential to suppress the autoimmune response that results in intestinal inflammation and cell pathogenesis in celiac patients. Sitari Pharmaceuticals, Inc. was founded in 2013 and is based in San Diego, California.
2 articles with Sitari Pharmaceuticals
GSK to obtain transglutaminase 2 small molecule program for celiac disease
Building on its unique six-year relationship with Avalon Ventures, GlaxoSmithKline will acquire San Diego-based Sitari Pharmaceuticals and its transglutaminase 2 small molecule program for celiac disease.